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Abstract
Introduction Gallstones are a known adverse effect of somatostatin analogs, but the exact incidence and clinical implica-
tions are unknown.
Objectives The aim of this study was to investigate the incidence of gallstones on imaging and related complications in 
unbiased trial data.
Methods Data from the DIPAK 1 trial, in which 305 polycystic kidney disease patients were randomized to standard of care 
(SoC) or lanreotide for 120 weeks, were used. Magnetic resonance imaging (MRI) was performed at baseline and end of 
treatment and was assessed for the presence, number, and size of gallstones. For all patients who had gallstones at the end 
of the trial, we obtained follow-up after the trial.
Results Of 249 patients with data available, 11 patients randomized to lanreotide and four randomized to SoC had gallstones 
at baseline. During the study, new gallstones were formed in 19/124 patients using lanreotide (15%) and 1/125 patients receiv-
ing SoC (1%). The odds ratio for gallstone formation with lanreotide use was 25.9 (95% confidence interval 3.37–198.8; 
p < 0.001). Gallstones during lanreotide treatment were multiple (> 20 stones in 69% of patients) and small (≤ 3 mm in 63% 
of patients). Of the 19 patients with incident gallstones during lanreotide treatment, 9 experienced gallstone-associated com-
plications, 8 of whom experienced gallstone-associated complications after discontinuation of treatment (median time after 
discontinuation 2.5 years). In patients with gallstones at baseline and in patients receiving SoC, no complications occurred.
Conclusions Treatment with a somatostatin analog leads to the formation of multiple, small gallstones that are associated 
with severe complications, especially after discontinuation of therapy.
Clinical Trial Registry Website and Trial Number ClinicalTrials.gov (https:// clini caltr ials. gov); NCT01616927.
A list of DIPAK consortium members is given in the 
Acknowledgments section.
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1 Introduction
Somatostatin analogs such as octreotide and lanreotide are 
available as treatment for several conditions such as acro-
megaly, neuroendocrine tumors, and dumping syndrome 
[1–6]. We recently executed a large randomized con-
trolled trial and demonstrated that the somatostatin analog 
Key Points 
During 2.3 years of lanreotide use, 15% of patients 
formed new gallstones, compared with 1% in untreated 
patients.
In most cases, these gallstones were multiple (>20) and 
small (≤3 mm).
About 50% of patients who developed gallstones during 
treatment experienced complications after discontinu-
ation, while no complications occurred in untreated 
patients or patients with gallstones present before the 
start of treatment.
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participating hospitals approved the protocol and all patients 
provided written informed consent. In the study, 305 patients 
with ADPKD (diagnosed according to the Ravine criteria), 
aged 18–60 years, and with a kidney function of 30–60 mL/
min/1.73m2 were included in four tertiary care hospitals in 
The Netherlands (Leiden, Rotterdam, Nijmegen, and Gron-
ingen). Patients with diabetes mellitus, a history of pancrea-
titis, known presence of gallstones, or bradycardia were not 
eligible. Patients were randomized to receive SoC, or SoC 
and, additionally, lanreotide 120 mg subcutaneously every 
4 weeks. If patients did not tolerate this dose, lanreotide 
was downtitrated to 90 mg or 60 mg, or stopped. Lanreo-
tide injections were continued for 120 weeks. MR images 
were made at baseline and at the end of treatment. For this 
post hoc analysis, all patients who previously underwent 
cholecystectomy, without a baseline or end-of treatment 
magnetic resonance imaging (MRI), or inability to identify 
the gallbladder at MRI, were excluded.
2.1  Procedures
MR images were made according to a standard protocol, 
including coronal and transversal T2-weighted single-shot 
fast gradient spin-echo images with fat saturation. All MRIs 
were scored independently by two trained observers who 
were blinded for patient identity, treatment allocation, and 
study phase. If the gallbladder could not be identified by 
one or both observers, or in case of inconsistencies between 
observers, a decisive evaluation was performed by an 
abdominal radiologist.
Patients finished trial treatment between November 2014 
and June 2016. For all patients with gallstones on imag-
ing at the end of the treatment period, additional follow-up 
data until January 2020 were obtained. Follow-up data were 
extracted from patient files. If these data were incomplete, 
patients were contacted by phone to obtain follow-up data.
2.2  Outcomes
The primary outcome was the incidence of gallstones during 
the trial, in patients using lanreotide compared with patients 
receiving SoC. Secondary outcomes were (1) the association 
of patient characteristics with gallstone formation, includ-
ing age, sex, body mass index (BMI), estimated glomerular 
filtration rate (eGFR), liver function tests, and baseline liver 
volume; (2) the number of gallstones, which was scored in 
classes of 1–5, 5–10, 10–15, 15–20, 20–25, 25–30, or > 30; 
(3) the size of the gallstones, which was scored in classes 
of ≤ 3 mm, > 3 and < 10 mm, and ≥ 10 mm; and (4) the 
incidence of biliary complications, such as biliary colic, 
cholecystitis, or biliary pancreatitis during and after the 
trial. Exploratory outcomes were the association between 
lanreotide also reduces liver growth in patients with poly-
cystic liver disease [7].
Gallstones are a known adverse event of somatostatin 
analog treatment that may cause acute biliary complications 
such as pancreatitis, cholecystitis, or biliary colics, but there 
is uncertainty about the incidence of these gallstones and 
the clinical consequences of this gallstone formation. In 
the studies that led to marketing authorization of somato-
statin analogs as treatment for neuroendocrine tumors (the 
PROMID and CLARINET trials, including 85 and 204 
patients and with a treatment duration of 1.8 and 1.2 years, 
respectively), incident gallstones were observed in 10% and 
12% of patients, respectively [2–5]. The current thinking 
is that these incident gallstones remain asymptomatic. In 
line, these landmark trials did not report complications, not 
even in the open-label follow-up phase [2–5]. However, in a 
recent retrospective study of somatostatin analogs as treat-
ment for neuroendocrine tumors (n = 300, median treat-
ment duration 3.5 years), a much higher incidence of gall-
stone formation (37%) and also a high incidence of biliary 
complications (28%) in patients with incident gallstones 
were reported [8]. However, this study was retrospective 
by design and based findings on symptoms only, not on 
systematic imaging. In a small case series it was suggested 
that complications of gallstones could also occur after dis-
continuation of somatostatin analogs [9]. This is important 
because most studies have no follow-up after discontinua-
tion of treatment. These data show that there is uncertainty 
about the exact incidence of gallstones and related biliary 
complications during and after treatment with somatostatin 
analogs.
We had access to unbiased data from the DIPAK 1 trial, 
a controlled trial in which patients with autosomal domi-
nant polycystic kidney disease (ADPKD) were randomized 
to lanreotide use or standard of care (SoC) with a relatively 
long treatment duration (2.3 years) and in which MR images 
were performed before and after treatment [10]. In the pre-
sent study, we used these data to determine the incidence, 
number, size, and complications of gallstones in a system-
atic, prospective way.
2  Methods
The design, methods, and results of the DIPAK 1 trial have 
been published previously [10, 11] (ClinicalTrials.gov: 
NCT01616927). In brief, this was an investigator-driven, 
randomized, open-label clinical trial with blinded endpoint 
analysis to assess the effect of lanreotide on rates of renal 
function decline and kidney and liver volume growth in 
patients with autosomal dominant polycystic kidney disease 
(ADPKD). The Institutional Review Board at each of the 
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gallstone formation and (1) response to therapy (indicated 
by change in liver volume during therapy); (2) hepatic cyst 
infections; (3) adverse events, such as abdominal pain, 
abdominal cramps, diarrhea, and discolored stool; and (4) 
the time period until complications developed.
2.3  Statistical Analysis
Analyses were performed using IBM statistics SPSS ver-
sion 23 (IBM Corporation, Armonk, NY, USA). Continuous 
data are presented as mean and standard deviation (SD) or 
as median and interquartile range (IQR) in the case of non-
normal distribution. Categorical data are presented as per-
centages. To test for differences in the presence of gallstones 
at baseline, end of study, and new gallstones formed during 
the trial in both groups (lanreotide vs. SoC only), Chi-square 
and Fisher’s exact tests were used. Logistic regression analy-
ses were performed to test for factors associated with gall-
stone formation. All authors had access to study data and 
reviewed and approved the final manuscript.
3  Results
A detailed flowchart of patients in this study is shown in 
Fig. 1. Of the 305 patients participating in the DIPAK 1 trial, 
29 patients were excluded because no MRI was available 
at baseline or end of treatment, 7 were excluded because 
of a medical history of cholecystectomy, and 20 patients 
were excluded due to inability to identify the gallbladder on 
MRI. Most of these latter patients had severe polycystic liver 
disease with many cysts in liver segments 4 and 5 adjacent 
to the gallbladder. An example of such a patient is shown 
in Fig. 2a.
Demographic and clinical characteristics of the 249 
patients at baseline according to randomization group are 
shown in Table 1. Characteristics of both groups were simi-
lar. All patients had ADPKD and thus progressive kidney 
disease, with a mean eGFR in both groups of approximately 
50 mL/1.73m2/min. There was a slight difference in the 
prevalence of mild, moderate, and severe polycystic liver 
disease between both groups. Mean aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT), alkaline 
phosphatase (ALP), γ-glutamyltransferase (GGT), and indi-
rect bilirubin values were comparable between the groups 
and within normal ranges; direct bilirubin levels differed 
significantly between the groups.
3.1  Primary Outcome
At baseline, 15 patients (6%) had gallstones on MR imaging, 
4 in the lanreotide group and 11 in the SoC group (Table 2). 
At the end of study (120 weeks), 34 (14%) patients had 
gallstones on MR imaging, 23 in the lanreotide group and 11 
in the SoC group. In the SoC group, gallstones disappeared 
during the study in one patient and incident gallstones 
formed in another patient. In the lanreotide group, no gall-
stones disappeared, and, during the study, 19 patients devel-
oped incident gallstones (15%) (Table 2). The difference in 
gallstone incidence between the two treatment groups was 
statistically significant (p < 0.0001). In one patient receiving 
SoC only, a gallstone in the common bile duct was observed; 
in all other patients, gallstones were observed in the gall-
bladder only.
3.2  Secondary Outcomes
In univariate logistic regression analysis, lanreotide use 
was significantly associated with the risk of gallstone 
formation (odds ratio [OR] 22.5, 95% confidence inter-
val [CI] 2.96–171; p < 0.01). In a multivariate logistic 
regression, lanreotide was again associated with gallstone 
formation, whereas other known risk factors for gallstone 
formation, such as female sex, age, and BMI were not sig-
nificantly associated nor showed interaction with lanreo-
tide use for the outcome of gallstone formation (Table 3). 
ALP, GGT, bilirubin level, baseline liver volume, and 
eGFR were also not significantly related with gallstone 
formation (Table 3).
In Table 4 and Fig. 3, the characteristics of incident 
gallstones during lanreotide treatment are compared with 
gallstones present at baseline and formed in the SoC group. 
Patients with gallstones at baseline had, in general, less and 
larger gallstones, whereas patients with gallstones formed 
during lanreotide treatment in general had several and small 
gallstones. Differences in stone size and number were signif-
icant (p = 0.001 and p = 0.004, respectively). Representative 
examples of patients with lanreotide-associated gallstones 
and gallstones at baseline are shown in Fig. 2.
Biliary complications were observed in nine patients 
(4%). All complications occurred in patients with incident 
gallstones during lanreotide treatment. No complications 
occurred in patients having gallstones at baseline persist-
ing during the study, neither in the lanreotide group nor the 
control group (p = 0.002) (Table 4). One patient developed 
a biliary pancreatitis during the treatment period while using 
lanreotide. This patient was admitted to hospital and the dis-
ease course was complicated by pneumonia. A month later, 
the patient was rehospitalized because of a gastropancreatic 
fistula, and shortly thereafter, a second readmission followed 
because of a necrotizing pancreatitis.
After the trial, complications occurred in an additional 
eight patients. There were no factors significantly associ-
ated with complications of incident gallstones. Median 
time between discontinuation of lanreotide and the devel-
opment of symptoms or complications was 2.5 years (IQR 
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1.0–3.6 years). For all patients, the timelines are shown in 
electronic supplementary Fig. 1.
Three patients developed a biliary pancreatitis, one 
of whom had to be admitted to an intensive care unit for 
4 months because of a severe necrotizing pancreatitis, com-
plicated by multi-organ failure, need for mechanical ventila-
tion, and recurrent bleeding from the distal colon, eventu-
ally treated by a colon resection and several reresections 
leading to a colostoma. A pancreatic deficiency resulted 
in diabetes mellitus. The second patient who experienced 
a pancreatitis was admitted to the hospital and developed 
bleeding after endoscopic retrograde cholangiopancreati-
cography (ERCP). In a second ERCP procedure, the bleed-
ing focus was coagulated. The laparascopic cholecystec-
tomy had to be converted to an open procedure because 
of the large kidney cyst volume. The third patient with a 
pancreatitis had a mild course and could be discharged from 
the hospital after 3 days. The patient underwent a chol-
ecystectomy but experienced a new episode of pancreatitis 
a year later, which was this time thought to be caused by 
propofol. Again, the patient experienced a fast recovery and 
was discharged after 4 days.
Fig. 1  Selection of patients 
from the DIPAK1 trial, used for 
this analysis. DIPAK Develop-
ing Interventions for Polycystic 
Autosomal Kidney disease, MRI 
magnetic resonance imaging, 
FU follow-up
305 paents 
randomized into the DIPAK1 trial
29 paents excluded
- 5 history of  
cholecystectomy
- 16 missing MRI at 
baseline or end of trial
- 8  gallbladder not 
visible at baseline or 
end of study MRI
153 paents received 
lanreode 
152 paents received 
standard of care 
27 paents excluded
- 2 history of  
cholecystectomy
- 13 missing MRI at 
baseline or end of trial
- 12   gallbladder not 
visible at baseline or 
end of study MRI
124 paents included in the 
analysis
125 paents included in the 
analysis 
23 paents having gallstones 
at the end of study 
11 paents having gallstones 
at the end of study 
19 paents incident 
gallstones











16 paents complete 
FU data
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Fig. 2  Representative magnetic resonance images at the end of 
the trial. The gallbladder is marked with a yellow line in all panels, 
except panel a. a An example of a patient with severe polycystic kid-
ney and liver disease in whom the gallbladder could not be identified 
due to the large number of cysts. b A patient with many small gall-
stones, treated with lanreotide, in whom the presence of gallstones is 
easily missed on coronal slices since the intensity of the gallstones 
is similar to the intensity of the liver parenchyma (b1). However, on 
axial slices, one can recognize the gallstones more easily because 
they are located at the dorsal side of the gallbladder due to gravity 
(b2). c Typical example of gallstones present at baseline (a limited 
number of larger stones). These stones mostly remained unchanged 
during the study period. d Typical example of gallstones formed dur-
ing lanreotide use (multiple small stones)
Table 1  Baseline characteristics
Data are expressed as means ± standard deviation or median (interquartile range) in the case of non-normal 
data distribution, or number (percentage) in the case of categorical data
Significant p-values are highlighted in bold
BMI body mass index, eGFR estimated glomerular filtration rate, hTLV height-adjusted liver vol-
ume, AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, GGT 




Standard of care [n = 125] p value
Female 58 (47) 62 (50) 0.66
Age, years 48 ± 7 49 ± 7 0.54
BMI, kg/m2 27.0 ± 4.2 27.2 ± 4.8 0.74
Height-adjusted total liver volume, mL 
[median (IQR)]
1165 (9868–1574) 1141 (962–1333) 0.06
Polycystic liver disease classification
 Mild [hTLV <1600 mL/m] 95 (76.6) 112 (89.6)
 Moderate [hTLV 1600–3200 mL] 24 (19.4) 11 (8.8)
 Severe [hTLV >3200 mL] 5 (4.0) 2 (1.6) 0.02
eGFR CKD-EPI, mL/1.73m2/min 50.4 ± 11.3 50.1 ± 11.1 0.82
AST, U/L [median (IQR)] 23.0 (19.5–27.5) 23.0 (20.0–28.0) 0.58
ALT, U/L [median (IQR)] 23.0 (18.0–29.0) 21.0 (16.0–27.0) 0.15
ALP, U/L [median (IQR)] 67.0 (56.0–80.0) 66.0 (55.3–77.8) 0.58
GGT, µmol/L [median (IQR)] 33.0 (23.5–49.0) 29.0 (1.25–47.0) 0.08
Bilirubin direct, µmol/L [median (IQR)] 3.0 (2.0–4.0) 3.0 (2.0–4.0) 0.008
Bilirubin indirect, µmol/L [median (IQR)] 6.0 (4.0–8.0) 6.0 (4.0–7.0) 0.57
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In addition, two patients developed cholecystitis, one a 
porcelain gallbladder, and another two patients had biliary 
colics. In all patients, a cholecystectomy was performed, and 
no further complications occurred.
3.3  Exploratory Outcomes
Adverse events that can be related to the presence of gall-
stones in patients using lanreotide are shown in electronic 
supplementary Table 1. Complaints such as abdominal pain, 
abdominal cramps, and discolored stool had a high preva-
lence, both in subjects with and without incident gallstones, 
possibly because these complaints can also be adverse 
effects of lanreotide. None of these symptoms was signifi-
cantly related to the presence or formation of gallstones. 
In a previous report on the DIPAK 1 trial, we described an 
increased incidence of hepatic cyst infections in lanreotide 
users [10, 12]. In the present analysis, hepatic cyst infections 
during lanreotide treatment were not related to the presence 
at baseline or incident gallstones during the study. The 
response to lanreotide treatment (assessed as the annual rate 
of liver growth) was not associated with incident gallstones.
4  Discussion
In the present study, we investigated the incidence of gall-
stones using systematic imaging in a relatively large-scale 
cohort of ADPKD patients who were randomized to lanreo-
tide or SoC. At the end of the 120-week lasting trial, 15% of 
patients in the lanreotide group had developed incident gall-
stones, compared with 1% of patients in the control group 
(OR 25.9, 95% CI 3.37–198.81). We showed that lanreotide-
associated gallstones were more often multiple (> 20) and 
small (≤ 3 mm). During the trial, one patient treated with 
lanreotide experienced a biliary pancreatitis. For patients 
with gallstones at the end of the trial, additional follow-up 
data until January 2020 were obtained. After discontinuation 
of therapy, an additional eight patients experienced acute bil-
iary complications, sometimes even years after discontinua-
tion. Complications only occurred in patients who developed 
gallstones during lanreotide treatment.
The incidence of gallstones during somatostatin analog 
treatment was previously systematically assessed using 
imaging in two studies [2, 13]. In the CLARINET study, 
the incidence of gallstones in patients treated with lanreotide 
was 12% in 1.2 years, similar to the 15% that we observed 
in our 2.3 years lasting trial. The CLARINET study did not 
report biliary complications [2]. In a prospective registry of 
patients treated with somatostatin analogs for acromegaly 
with yearly ultrasound assessments, 33/91 patients formed 
new gallstones (36%) [13]; however, follow-up time was 
longer (median 11 years) and acromegaly is a risk factor for 
gallstone formation [14]. In this study, there was no follow-
up after the cessation of treatment [13].
A strength of our study is that we obtained data about 
gallstone-related complications not only during but also 
after the end of the formal trial period when medication was 
withdrawn. During the treatment period, only one patient 
developed an acute biliary pancreatitis. However, after the 
formal trial period, an additional three patients experienced 
a pancreatitis, two patients experienced biliary colic, two 
Table 2  Presence of gallstones 
at baseline and end of study, 
and incidence of gallstones 
compared in the lanreotide and 
control groups
Significant p-values are highlighted in bold
a In one patient, a gallstone disappeared, and another patient receiving standard of care had incident gall-
stones
Lanreotide [n = 124] Standard of care 
[n = 125]
p value
Gallstones at baseline 4 (3.2) 11 (8.8) 0.07
Gallstones at end of study 23 (18.5) 11 (8.8) < 0.05
New gallstones during study 19 (15.3) 1a (0.8) < 0.0001
Table 3  Logistic regression to assess the risk associated with lanreo-
tide use for incident gallstones
Significant factors via multivariable analysis are highlighted in bold
OR odds ratio, CI confidence interval, BMI body mass index, eGFR 
estimated glomerular filtration rate, as calculated using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
a Interaction terms for sex * lanreotide and BMI * lanreotide were not 
significant
OR (95% CI) p value
Univariate
Lanreotide use 22.5 (2.96–171) < 0.01
Multivariate
Lanreotide use 25.9 (3.37–199) < 0.01
Female  sexa 1.66 (0.59–4.66) 0.33
Age, years 1.04 (0.97–1.12) 0.28
BMI, kg/m2a 0.95 (0.83–1.09) 0.46
Baseline liver volume (ml) 1.00 (1.00–1.00) 0.16
Baseline eGFR (ml/1.73m2/min) 1.00 (0.96–1.05) 0.90
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patients experienced an acute cholecystitis, and one patient 
developed a porcelain gallbladder. All nine complications 
occurred in the 19 patients with incident gallstones during 
lanreotide treatment. Median time between discontinua-
tion of treatment and the acute biliary complications was 
2.5 years.
The complication rate of these gallstones formed during 
somatostatin analog treatment is much higher than the com-
plication rate of gallstones identified by routine screening 
in the general population. Such gallstones in general lead to 
symptoms in only 1–4% of patients per year, and to compli-
cations in only 0.1–0.3% per year in asymptomatic patients 
and 1–3% per year in symptomatic patients [15]. The high 
complication rate associated with incident gallstones during 
lanreotide treatment raises concern because pancreatitis in 
particular can be a severe complication, with a mortality rate 
of up to 5–10% [16].
The high complication rate in these patients with incident 
gallstones during lanreotide treatment may be explained by 
stone characteristics. Incident gallstones during lanreotide 
treatment were high in number (> 20 gallstones) and smaller 
(≤ 3 mm) than gallstones present before the start of treat-
ment (Table 4 and Fig. 3). It has previously been shown 
that small gallstones in particular are associated with acute 
Table 4  Characteristics of 
incident gallstones during 
lanreotide treatment versus 
gallstones that were present at 
baseline and persisted during 
the trial
Data are expressed as n (%)
Significant p-values are highlighted in bold
a One patient developed pancreatitis during lanreotide treatment; all other complications occurred after the 
cessation of therapy
Incident gallstones during lanreotide 
treatment [n = 19]
Gallstones at baseline 
[n = 14]
p value
Number of gallstones 0.004
 1–5 4 (21) 9 (64)
 5–10 0 (0) 1 (7)
 10–15 1 (5) 3 (21)
 15–20 1 (5) 0 (0)
 20–25 4 (21) 1 (7)
 25–30 2 (11) 0 (0)
 30+ 7 (37) 0 (0)
Gallstone size, mm 0.001
 ≤ 3 12 (63) 2 (14)
 3–10 7 (37) 6 (43)
 ≥ 10 0 (0) 6 (43)
 Follow-up data available until 
January 2020
16 (84) 13 (93)
 Complications 9 (56) 0 0.002
  Pancreatitisa 4 (25) 0
 Cholecystitis 2 (13) 0
 Biliary colic 2 (13) 0
 Porcelain gallbladder 1 (6) 0
Fig. 3  Differences in the 
number and size of incident 
gallstones in patients receiv-
ing lanreotide compared with 
other gallstones. Size of the 
gallstones and the number of 
gallstones differed significantly 
between patients with incident 
gallstones receiving lanreo-
tide, and gallstones that were 
present at baseline and persisted 
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biliary complications such as biliary pancreatitis [17]. It is 
assumed that these smaller stones can migrate more easily 
into the common bile duct than larger stones and might more 
often cause a distal obstruction of the pancreatic duct at the 
level of the sphincter of Oddi [17, 18].
In our study, most acute biliary complications occurred 
after discontinuation of somatostatin analog therapy. This 
could potentially be explained by the effect of these drugs on 
gallbladder motility. Gallstone formation during treatment 
with somatostatin analogs is promoted by increased forma-
tion of cholesterol-rich crystals in the bile and inhibition 
of postprandial gallbladder motility and impaired relaxa-
tion of the sphincter of Oddi, particularly through inhibi-
tory effects on cholecystokinin (CCK) release [18–21]. As 
a consequence, stasis of bile occurs, leading to increased 
gallstone formation. After cessation of therapy, gallbladder 
motility will return, which can lead to expulsion of gallblad-
der stones, and thereby to complications. This mechanism is 
known in biliary pancreatitis, where gallbladder motility is 
an important risk factor [17, 18]. Trials where somatostatin 
analogs were used did not report these acute biliary compli-
cations, which may be caused by the fact that follow-up after 
discontinuation of treatment was not performed and that in 
neuroendocrine tumors and acromegaly, most patients con-
tinue therapy. In our trial, almost all patients discontinued 
treatment and follow-up was available after the formal end 
of the trial.
We showed that complaints caused by gallstones may 
be difficult to distinguish from lanreotide-related adverse 
effects. In patients with polycystic kidney or liver disease, 
gallstones may be even more difficult to recognize because 
these patients often experience abdominal pain due to their 
cystic disease.
What may the practical consequences of our findings be? 
We showed that the asymptomatic gallstones present before 
the start of treatment do not carry a high complication risk, 
in contrast to incident gallstones. Therefore, the presence 
of asymptomatic gallstones before the start of treatment 
may not necessarily be a contraindication for the start of 
somatostatin analogs, as is assumed at present. An important 
finding is that complications of incident gallstones occur 
mostly after cessation of lanreotide therapy. Therefore, in 
case of gallstone formation during somatostatin analog 
therapy, discontinuation of this treatment should be done 
with caution because discontinuation of therapy seems not to 
prevent, but may rather provoke, complications. In patients 
with incident gallstones during somatostatin analog treat-
ment, it may be worthwhile to start ursodeoxycholic acid 
(UDCA), especially if there is an indication to discontinue 
lanreotide. This drug does not reduce complaints caused by 
symptomatic gallstones [22]. However, we showed that the 
asymptomatic gallstones associated with somatostatin ana-
logs are mostly small and have therefore a large surface area 
compared with their content. It could well be that UDCA is 
effective in dissolving these specific gallstones [23]. Another 
option could be to discuss with a surgeon whether prophy-
lactic cholecystectomy may be indicated and feasible in this 
specific patient.
The strengths of our study are that we determined the 
incidence of gallstones not only based on symptoms but also 
on MR images. Next, we obtained data on the number and 
size of these gallstones, and obtained data on acute biliary 
complications, even after discontinuation of therapy, which 
is mostly not available.
A limitation of this study could be that we studied only 
lanreotide. Because the mechanism of gallstone formation 
is similar for all somatostatin analogs [18–21], we expect 
that our results are not specific for lanreotide but are class-
dependent. In this trial, patients with symptomatic gallstones 
were excluded. This could explain the low prevalence of 
gallstones at baseline and indicates that we can draw con-
clusions on patients with baseline asymptomatic gallstones 
only. Finally, our study was performed in a specific patient 
population. However, from the literature, it is not known that 
patients with ADPKD have a higher risk of gallstone forma-
tion or complication rate per se. We therefore believe that 
our results are also applicable to other patient populations.
5  Conclusion
The present study shows that the somatostatin analog lan-
reotide led to gallstone formation in about 15% of treated 
patients, of whom about half developed potentially severe 
complications. Because patients with asymptomatic gall-
stones present on imaging before the start of somatostatin 
analog treatment did not develop complications, the pres-
ence of these asymptomatic gallstones may not be a con-
traindication to the start of somatostatin analogs. Complica-
tions mostly occurred after the discontinuation of treatment 
in patients with incident gallstones during somatostatin 
analog treatment. In such patients, starting UDCA may 
be an option before stopping the somatostatin analog. It 
is important to be aware of the high risk of acute biliary 
complications of somatostatin analog-associated gallstones, 
especially after discontinuation of treatment, and to counsel 
patients carefully.
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